# Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer

> **NCT07049133** · — · RECRUITING · sponsor: **European Institute of Oncology** · enrollment: 84 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **OTHER:** T-DXd toxicity marker identification

## Key facts

- **NCT ID:** NCT07049133
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07049133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07049133, "Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07049133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*